Microbiome venture can start production in Denmark and Switzerland

The Danish Medicines agency has inspected Bacthera, a joint venture between Danish enzyme giant Chr. Hansen and Swiss Lonza, and has authorized the company to start producing bacteria for medical purposes in Denmark. The Swiss health authorities have also given the go-ahead.
Photo: Lonza / PR
Photo: Lonza / PR
BY ALBERT RØNNING ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

Bioscience company Chr. Hansen and Swiss biotech firm Lonza have obtained permission to launch the production of bacteria for pharmaceutical use in their production facilities in Denmark and Switzerland.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading